In order to understand the impact of caspase-5 in NSCLC, we used a caspase-5 antibody to test via an ELISA assay the presence of this enzyme in tumor tissues compared to caspase-4, which was detected by means of ELISA by using a specific antibody, different from what is commercially available, actually under patent (RM2014A000080 and PCT/IB2015/051262). Here, CASP5 is linked to neoplasm.